Alembic Pharmaceuticals Limited (APLLTD) Earnings Call Transcripts

Alembic Pharmaceuticals Limited's Latest Earnings Call - Q4 FY2026

Alembic Pharmaceuticals Limited reported its Q4 FY '26 earnings with revenue from operations at INR 1,848 crores, marking a 4% year-on-year increase. The quarter was characterized by new launches in the U.S. and volume-led growth in API and Animal Health, partially offset by pricing pressures. EBITDA before R&D rose by 8% to INR 455 crores, with core margins at 25%. The company provided a directional outlook for FY '27, targeting low double-digit top-line growth, driven by strategic investments and operational improvements.

Reported metrics

Guidance from management

Alembic Pharmaceuticals expects low double-digit top-line growth for FY '27, with margin protection and capital-efficient execution. The U.S. branded business is expected to scale up, and R&D investments are projected at INR 750-800 crores.

What management said

So, Rahul, it's a little tough to say, because I think, what's happening is a lot of the filings that happened there, especially from the new facilities, let's say, the penems and everything, they're all late expiry. I think the whole point of the penems facility was that it's -- we are locking in some of the day 1. I think you will see one of them, 1 launch happening in the end of this quarter. So, it's still tough ...

Yes. I think -- again, it's not a guidance, but just the way I see the business right now, we'll definitely have growth in the market. Yes, that's one way of looking at it. I'm saying, yes, in terms of INR terms, I mentioned 10% to 15%.

What analysts pressed on

Analysts expressed concerns about the underutilization of facilities F2 and F3 pending FDA approvals and the impact of the U.S. Specialty business on margins. Questions also focused on the productivity of increased R&D investments and the timeline for these investments to yield returns.

Main topics on the call

• India Business Performance — The India business grew by 4% YoY in Q4, supported by price-led growth and new launches, with Specialty Therapies and Animal Healthcare performing well. Management noted, 'Operationally in the India business on a firmer ...
• International Business Growth — The international business showed positive growth, with the U.S. market benefiting from volume and new launches. Ex-U.S. markets grew 20% for the year, though Q4 was muted due to a higher base.
• U.S. Branded Business Launch — The U.S. branded business, including the launch of Pivya, began operations in Q4. Management acknowledged a 'drag in the quarter due to the Alembic Therapeutics business,' but expects improvement by year-end.
• R&D Investment Increase — R&D spending increased to INR 209 crores, representing 11% of revenue, up from 9% last year, driven by peptide-related development activities. Management plans R&D investments of INR 750-800 crores for FY '27.

Read the full Alembic Pharmaceuticals Limited transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 25 Alembic Pharmaceuticals Limited earnings call transcripts on record, spanning January 22, 2020 to August 4, 2026. Based on this history, Alembic Pharmaceuticals Limited reports quarterly. The most recent call on file is dated August 4, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

APLLTD

Exchange

NSEI

Country

IN

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

25

First call

January 22, 2020

Most recent

August 4, 2026

Reporting cadence

quarterly